NeuroSense Therapeutics Achieves Landmark Biomarker Discoveries in Alzheimer's Disease Treatment
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) has unveiled promising biomarker findings from its Phase 2 RoAD study focusing on Alzheimer's disease (AD), a progressive neurodegenerative disorder affecting millions worldwide. The trial, which included eight participants, aimed to evaluate the safety and efficacy of its investigational drug, PrimeC.
In this double-blind, placebo-controlled study, participants were divided into two groups, one receiving PrimeC and the other a placebo. Following a 12-month follow-up, comprehensive analyses were conducted on cerebrospinal fluid (CSF) and plasma samples from three participants. The results indicated notable changes in key protein biomarkers associated with AD. These alterations primarily included shifts in brain-derived tau and phospho-tau, alongside an adjustment in the amyloid beta protein ratio, pivotal in AD pathology.
Additional noteworthy changes were also observed in proteins linked to other neurodegenerative diseases, such as alpha-synuclein and TAR DNA-binding protein 43 (TDP-43), which are typically associated with conditions like amyotrophic lateral sclerosis (ALS) and Parkinson's disease. These biomarker shifts potentially suggest an interconnected pathway among various neurodegenerative diseases, reinforcing the need for multi-target therapies like PrimeC.
Alon Ben-Noon, Co-Founder and CEO of NeuroSense, highlighted the significance of these findings. He stated, "The initial results from the RoAD study suggest that the multi-target mechanism we have been pursuing in ALS is also engaging biology crucial to Alzheimer's. While this exploratory study had a limited patient sample, the biological signals we observe across two distinct neurodegenerative conditions bolster our confidence in PrimeC's strategy."
Professor Steven E. Arnold, a member of NeuroSense's Scientific Advisory Board, added, "These early biomarker data suggest broad impacts on neuron health and proteostasis consistent with what we believe is PrimeC's mechanism of action. However, these results warrant further evaluation in larger studies to determine if the observed effects can translate into clinical benefits for patients."
NeuroSense aims to leverage these positive findings to guide the planning of a future, well-structured clinical trial examining PrimeC's efficacy in AD. With a pressing need for effective treatments for Alzheimer's—more than 30 million people are affected globally and current therapies only provide limited symptomatic relief—NeuroSense’s multi-target approach could represent a significant advancement in treatment options.
PrimeC is crafted as an extended-release oral formulation that combines two previously FDA-approved medications, ciprofloxacin and celecoxib. This unique formulation is designed to tackle various mechanisms implicated in neuron degeneration, thereby potentially slowing or halting disease progression in both AD and ALS.
NeuroSense remains focused on addressing the complexities surrounding neurodegenerative diseases. Their strategy centers on developing combination therapies that target multiple pathways, reflecting the intricate nature of these conditions and the substantive unmet need for effective therapeutics. As they move forward with their clinical programs, they continue to engage with both scientific and regulatory stakeholders to advance their mission.
The RoAD study (NST-AD-001) serves as a stepping stone in NeuroSense's research journey, with the company's commitment to harnessing innovative solutions in biomedical science signaling hope for countless patients and caregivers affected by Alzheimer’s disease. The findings present a beacon of optimism in a field where effective treatments remain critically needed. NeuroSense's progress could mark a transformative phase in the ongoing fight against Alzheimer’s and other neurodegenerative disorders.
In this double-blind, placebo-controlled study, participants were divided into two groups, one receiving PrimeC and the other a placebo. Following a 12-month follow-up, comprehensive analyses were conducted on cerebrospinal fluid (CSF) and plasma samples from three participants. The results indicated notable changes in key protein biomarkers associated with AD. These alterations primarily included shifts in brain-derived tau and phospho-tau, alongside an adjustment in the amyloid beta protein ratio, pivotal in AD pathology.
Additional noteworthy changes were also observed in proteins linked to other neurodegenerative diseases, such as alpha-synuclein and TAR DNA-binding protein 43 (TDP-43), which are typically associated with conditions like amyotrophic lateral sclerosis (ALS) and Parkinson's disease. These biomarker shifts potentially suggest an interconnected pathway among various neurodegenerative diseases, reinforcing the need for multi-target therapies like PrimeC.
Alon Ben-Noon, Co-Founder and CEO of NeuroSense, highlighted the significance of these findings. He stated, "The initial results from the RoAD study suggest that the multi-target mechanism we have been pursuing in ALS is also engaging biology crucial to Alzheimer's. While this exploratory study had a limited patient sample, the biological signals we observe across two distinct neurodegenerative conditions bolster our confidence in PrimeC's strategy."
Professor Steven E. Arnold, a member of NeuroSense's Scientific Advisory Board, added, "These early biomarker data suggest broad impacts on neuron health and proteostasis consistent with what we believe is PrimeC's mechanism of action. However, these results warrant further evaluation in larger studies to determine if the observed effects can translate into clinical benefits for patients."
NeuroSense aims to leverage these positive findings to guide the planning of a future, well-structured clinical trial examining PrimeC's efficacy in AD. With a pressing need for effective treatments for Alzheimer's—more than 30 million people are affected globally and current therapies only provide limited symptomatic relief—NeuroSense’s multi-target approach could represent a significant advancement in treatment options.
PrimeC is crafted as an extended-release oral formulation that combines two previously FDA-approved medications, ciprofloxacin and celecoxib. This unique formulation is designed to tackle various mechanisms implicated in neuron degeneration, thereby potentially slowing or halting disease progression in both AD and ALS.
NeuroSense remains focused on addressing the complexities surrounding neurodegenerative diseases. Their strategy centers on developing combination therapies that target multiple pathways, reflecting the intricate nature of these conditions and the substantive unmet need for effective therapeutics. As they move forward with their clinical programs, they continue to engage with both scientific and regulatory stakeholders to advance their mission.
The RoAD study (NST-AD-001) serves as a stepping stone in NeuroSense's research journey, with the company's commitment to harnessing innovative solutions in biomedical science signaling hope for countless patients and caregivers affected by Alzheimer’s disease. The findings present a beacon of optimism in a field where effective treatments remain critically needed. NeuroSense's progress could mark a transformative phase in the ongoing fight against Alzheimer’s and other neurodegenerative disorders.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.